WO2014137395A1 - Salicylic acid gel - Google Patents
Salicylic acid gel Download PDFInfo
- Publication number
- WO2014137395A1 WO2014137395A1 PCT/US2013/062561 US2013062561W WO2014137395A1 WO 2014137395 A1 WO2014137395 A1 WO 2014137395A1 US 2013062561 W US2013062561 W US 2013062561W WO 2014137395 A1 WO2014137395 A1 WO 2014137395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salicylic acid
- gel
- total weight
- solvent
- acid gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Definitions
- the invention relates to a gel of salicylic acid, and products produced therefrom.
- Salicylic acid also known as 2-hydroxybenzenecarboxylic acid, is a monohydroxybenzoic acid. Its salts and esters are known as salicylates. Salicylic acid has the formula:
- Salicylic acid is also known for providing pain relief when applied as a liniment, for example
- Salicylic acid is used in many skin-care products.
- salicylic acid is well known for its use in anti-acne treatments.
- salicylic acid is also used in products for treatment of psoriasis, calluses, corns, keratosis pilaris, and warts. It works as a keratolytic, bacteriocide and comedo lytic agent.
- Salicylic acid is also used in shampoos for treatment of dandruff and as a chemical exfoliant.
- Salicylic acid can cause burns if applied in high concentrations. Typically, over-the- counter limits are 2% for topical treatments (that remain on the skin) and 3% for cleansers or shampoo (products that are washed off.) Higher concentrations (e.g. up to 40 wt %) may be used for wart removal but should be applied cautiously and only to the wart and not the surrounding skin.
- Salicylic acid is poorly soluble in water. It is therefore difficult to prepare solutions of salicylic acid that remain precipitate-free.
- the present invention is directed to a salicylic acid gel consisting of salicylic acid and a stabilizer compound, wherein the salicylic acid is present in at least 1 wt% based on total weight of the gel.
- the present invention is further directed to a salicylic acid solution comprising the salicylic acid gel and a solvent.
- the present invention is further directed to products prepared with the salicylic acid gel or with dilute solutions of the gel.
- the present invention is further directed to a salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt%, based on total weight of the gel.
- the present invention is further directed to a salicylic acid solution comprising the salicylic acid gel and a solvent.
- the present invention is further directed to products prepared with the salicylic acid gel or with dilute solutions of the gel in solvent.
- the present invention is further directed to a salicylic acid gel consisting of salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt%, based on total weight of the gel.
- the salicylic acid gel prepared in accordance with any aspect above is combined with ingredients to form various products including body or hand lotions, anti- dandruff shampoos, wart medications, and anti-acne medications.
- aspects of the invention are directed to a gel of salicylic acid and at least one stabilizer compound selected from nitrogen compounds.
- One aspect is particularly directed to a concentrated gel.
- the concentrated gel allows relatively large amounts of salicylic acid to be shipped and stored in a safe and stable manner. A higher concentration of salicylic acid further allows smaller shipping and storage space.
- Another aspect is directed to gel consisting of salicylic acid and at least one stabilizer compound selected from nitrogen compounds. This gel also allows salicylic acid to be shipped and stored in a safe and stable manner. In addition, the gel is flowable so is easier to manufacture and use.
- a (concentrated) salicylic acid gel comprises at least 30 wt% salicylic acid, at least 35 wt%, or at least 40 wt% salicylic acid gel, for example 30 wt% to 60 wt% salicylic acid, or 35 wt% to 55 wt%, or 40 to 55 wt% salicylic acid each based on total weight of the gel. Specific amounts may be 30 wt%, 35 wt%, 40 wt%, 50 wt%, and 60 wt% based on total weight of the gel based on total weight of the gel.
- the concentrated salicylic acid gel comprises the stabilizer compound in an amount of at least 40 wt%, at least 45 wt%, at least 60 wt%, and up to 70 wt%, for example 40 to 70 wt%, or 45 to 60 wt%, each based on total weight of the gel which is an amount effective to provide stability to the salicylic acid in the gel.
- Specific amounts may be 40 wt%, 50 wt%, 60 wt%, 65 wt%, and 70 wt% based on total weight of the gel.
- the concentrated salicylic acid gel is formed by mixing salicylic acid with the stabilizer compound until the salicylic acid is dissolved in the stabilizer compound.
- no water or solvent such as ethanol is included in the gel.
- no other active ingredient is present in the gel.
- the stabilizer compound complexing agent
- the salicylic acid gel consists of salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt%, based on total weight of the gel.
- the mixing of the salicylic acid and the stabilizer compound may be done at room temperature. Alternatively the mixing may occur at an elevated temperature such as up to 50° C. Generally mixing takes about 30 to 120 minutes. [017]
- the concentrated gel may then be stored for future use. A benefit of the concentrated gel is that such gel contains very concentrated amounts of salicylic acid, and less storage space is required than dilute solutions of salicylic acid. The gel is storage stable for at least 2 years.
- the stabilizer compound may be any suitable nitrogen compound that stabilizes the salicylic acid in the concentrated gel.
- Nitrogen compounds useful to form the highly concentrated salicylic gel include, but not limited to, alkoxylated amides, alkoxylated amines, alkyl-substituted amino acids, alkylamido alkylamines, amides, amine oxides, amines, and betaines. Ideally, a clear product should be produced.
- the nitrogen compound is cocamidopropyl dimethylamine.
- the cocamidopropyl dimethylamine is particularly suitable for high concentrations of salicylic acid. When diluted in water, the resulting solution is stable and clear.
- the concentrated gel can be diluted to any suitable level for use. Dilution of the salicylic acid gel may occur by the addition of water, a short chain alcohol such as ethanol and isopropanol, or any combination thereof. Upon dilution, the salicylic acid forms a clear, stable solution in the water or alcohols - that is, the salicylic acid does not precipitate out.
- a short chain alcohol such as ethanol and isopropanol
- the dilute solutions comprise wherein the concentration of the salicylic acid in the solution is at least 0.5 wt%, at least 1 wt%, at least 5 wt%, at least 10 wt%, at least 15 wt% or at least 20 wt% each based on total weight of the solution.
- the present invention is further directed to products prepared with the salicylic acid gel or with dilute solutions of the gel in solvent wherein the concentration of the salicylic acid in the product is at least at least 0.5 wt%, at least 1 wt%, at least 5 wt%, at least 10 wt%, at least 15 wt%, at least 20 wt%, at least 30 wt%, or at least 40 wt% each based on total weight of the product.
- compositions of the invention are directed to a gel consisting of salicylic acid and at least one stabilizer compound selected from nitrogen compounds.
- the gel allows salicylic acid to be shipped and stored in a safe and stable manner.
- the salicylic acid gel consists of at least 1 wt%, at least 5 wt%, at least 10 wt%, at least 15 wt%, or at least 20 wt%, salicylic acid based on total weight of the gel. Specific amounts may be, but not limited to, lwt%, 5 wt% 10 wt%, or 20 wt%.
- the salicylic acid gel consists of the stabilizer compound in an amount of at least 30 wt%, at least 80 wt%, at least 90 wt%, at least 95 wt%, at least 99 wt%, and up to 99 wt%, for example between 70 wt% and 99 wt%.
- the salicylic acid gel is formed by mixing salicylic acid with the stabilizer compound until the salicylic acid is dissolved in the stabilizer compound. No water or solvent such as ethanol is included in the gel.
- the mixing of the salicylic acid and the stabilizer compound may be done at room temperature. Alternatively the mixing may occur at an elevated temperature such as up to 50° C. Generally mixing takes about 3 to 120 minutes.
- the gel may be stored.
- the stabilizer compound may be any suitable nitrogen compound that stabilizes the salicylic acid in the gel as discussed above and incorporated by reference herein.
- the gel can be diluted to any suitable level for use such as by the addition of water, a short chain alcohol such as ethanol and isopropanol, or any combination thereof.
- the dilute solutions comprise wherein the concentration of the salicylic acid in the solution is at least 0.5 wt%, at least 1 wt%, at least 5 wt%, at least 10 wt%, at least 15 wt% or at least 20 wt% each based on total weight of the solution.
- the salicylic acid forms a clear, stable solution in the water or alcohols.
- the present invention is further directed to products prepared with the salicylic acid gel or with dilute solutions of the gel in solvent wherein the concentration of the salicylic acid in the product is at least at least 0.5 wt%, at least 1 wt%, at least 5 wt%, at least 10 wt%, at least 15 wt% or at least 20 wt% each based on total weight of the product.
- the pH of the dilute system is generally less than 5, such as 2 to 5, 2.5 to 4.5, typically 3 to 4.
- the dilute system must pass the USP Monograph for a Salicylic Gel which includes an assay for salicylic acid.
- the diluted product may be combined with other suitable ingredients to form the final products such as creams, lotions, make-ups, toners, astringents, skin cleansing compositions, shampoos, and conditioners. These compositions contain about 0.1-40 wt% of salicylic acid. The amount of salicylic acid in the final product depends on the intended purpose of the product.
- Creams typically contain about 10-90 wt% water and 10-90 wt% oil. Creams may also contain humectants, emollients, surfactants, emulsifiers, preservatives and fragrances. Creams would generally contain from 0.1 to 5 wt% salicylic acid.
- Lotions typically contain 20-80 wt% oil and 10-80 wt% water in an emulsion form.
- lotions may contain humectants, emollients, surfactants, fragrances, preservatives and so forth.
- Creams would generally contain from 0.2 to 5 wt% salicylic acid.
- Make-ups typically contain about 5-70 wt% oil, 10-95 wt% water, and about 5-40 wt% pigment.
- the makeup may contain surfactants, silicones as part of the oil phase, humectants, emollients, preservatives, fragrances, etc. Make-up would generally contain from 0.1 to 3 wt% salicylic acid.
- Anti-dandruff shampoos typically contain 1-40 wt% of a cleansing surfactant and 10-90 wt% water.
- the shampoo may also contain any one of ingredients such as surfactants, colorants, preservatives, fragrance, emulsifiers, viscosity adjusters, and conditioning agents.
- Anti-dandruff shampoos would generally contain from 0.18 to 3 wt% salicylic acid.
- Hair conditioners typically contain include 10-95 wt% water, 0.5-30 wt% conditioning ingredients such as quaternary ammonium compounds or amphoteric polymers, proteins, etc., and 1-40% surfactants. Hair conditioners may also contain volatile or nonvolatile silicones. Hair conditioners would generally contain from 0.1 to 4 wt% salicylic acid.
- Toners typically contain about 0-85 wt% alcohol, 0.01-5 wt% surfactant, and 0.1-5 wt% humectants, 0.1-85% water.
- the salicylic acid may also be used in ointments, gels, or solutions.
- Suitable ointments are hydrophilic ointments (USP) or petroleum.
- the amount of salicylic acid present in the final product depends on the product.
- acne treatment products generally contain 0.5 to 2 wt% salicylic acid
- dandruff and seborrheic dermatitis and psoriasis treatment products generally contain 3 wt% salicylic acid
- wart treatments generally contain up to 40 wt% salicylic acid, typically 5 wt% to 40 wt% or 17 wt% to 25 wt%.
- the concentrated gel was diluted to 2 wt% active salicylic acid in water and separately in ethanol.
- the resulting solutions were clear and colorless. No precipitate was formed either in water or in ethanol.
- the pH of the water solution was approximately 3.2.
- the gel was also diluted to 25 wt% active salicylic acid in water.
- the resulting solution was a slightly viscous, yellow, clear solution. No precipitate was formed.
- a physical accelerated stability test was run on this prototype consisting of samples be held at 50°C for two weeks and another sample run through five freeze/thaw cycles. Under both of these conditions there were no physical changes to the product include pH, viscosity, color and appearance.
- a lotion was prepared with 5% of the gel of example 1 in 91% water with 4% Egel 305 [Polyacrylamide (&) CI 2- 13 isoparaffm (&) Laureth-7].
- the result was a white lotion that would be applicable for an anti-acne product. It underwent the same accelerated stability testing as mentioned above (50°C for 2 weeks and 5 freeze/thaw cycles); there were no significant physical changes to the product during the stability testing.
- Example 3 An anti-dandruff shampoo was prepared containing 3 wt% salicylic acid.
- Sulfochem B-NBB, Glucamate LT and Nipaguard PDU were added and mixed until homogenous. Then citric acid was added, with continued mixing, until the batch reached pH of approximately 4.0. Viscosity: >1300cp. Stability: Passed 2 weeks 50°C; 5 Freeze/ Thaw cycles.
- a wart remover was prepared containing % salicylic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13776659.8A EP2964189B1 (en) | 2013-03-08 | 2013-09-30 | Salicylic acid gel |
| CN201380075628.1A CN105517535A (en) | 2013-03-08 | 2013-09-30 | Salicylic acid gel |
| BR112015021565-3A BR112015021565B1 (en) | 2013-03-08 | 2013-09-30 | COMPOSITION IN THE FORM OF A STABLE GEL, METHOD FOR PREPARING A DILUTED COMPOSITION CONTAINING SALICYLIC ACID, COMPOSITION COMPRISING A STABLE SOLUTION AND PRODUCT |
| MX2015011497A MX373541B (en) | 2012-03-27 | 2013-09-30 | Salicylic acid gel |
| US14/329,063 US20140323445A1 (en) | 2012-03-27 | 2014-07-11 | Salicylic Acid Gel |
| US17/373,070 US12318461B2 (en) | 2012-03-27 | 2021-07-12 | Salicylic acid gel |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615956P | 2012-03-27 | 2012-03-27 | |
| US13/789,780 US8828979B2 (en) | 2012-03-27 | 2013-03-08 | Salicylic acid gel |
| US13/789,780 | 2013-03-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/789,780 Continuation-In-Part US8828979B2 (en) | 2012-03-27 | 2013-03-08 | Salicylic acid gel |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/329,063 Continuation-In-Part US20140323445A1 (en) | 2012-03-27 | 2014-07-11 | Salicylic Acid Gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014137395A1 true WO2014137395A1 (en) | 2014-09-12 |
Family
ID=49235845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2013/062561 Ceased WO2014137395A1 (en) | 2012-03-27 | 2013-09-30 | Salicylic acid gel |
Country Status (3)
| Country | Link |
|---|---|
| US (4) | US8828979B2 (en) |
| MX (1) | MX373541B (en) |
| WO (1) | WO2014137395A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180311136A1 (en) * | 2017-04-26 | 2018-11-01 | The Procter & Gamble Company | Compositions with a thickening polymer |
| KR102041389B1 (en) | 2017-12-12 | 2019-11-27 | (주)프론트바이오 | N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide and 2-((9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl) carbamoyl)phenyl acetate compound, and method for producing the same, and composition for the anti-inflammatory and analgesia comprising the same |
| US12226505B2 (en) | 2018-10-25 | 2025-02-18 | The Procter & Gamble Company | Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents |
| RU2708250C1 (en) * | 2019-03-15 | 2019-12-05 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Method of producing chemical peeling gel |
| CN114569494B (en) * | 2022-04-29 | 2022-08-09 | 广东一芙化妆品有限公司 | Composition for removing makeup, preparation method, packaging method and using method thereof, and makeup removing gel |
| WO2024087150A1 (en) * | 2022-10-28 | 2024-05-02 | L'oreal | Composition for conditioning the hair |
| CN116585207B (en) * | 2023-04-24 | 2024-11-15 | 上海其然生物科技有限公司 | A transparent and uniform salicylic acid preparation and its preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0052705A1 (en) * | 1980-11-24 | 1982-06-02 | Joel E. Bernstein, M.D. | Composition for treating acne vulgaris |
| WO1998052927A1 (en) * | 1997-05-19 | 1998-11-26 | Rosemarie Scivoletto | Composition for treating skin conditions |
| WO2000002593A2 (en) * | 1998-07-09 | 2000-01-20 | Transphyto S.A. | Cleansing and treating lotion for treating comedones |
| EP1795181A1 (en) * | 2005-12-05 | 2007-06-13 | L'Oréal | Cosmetic and pharmaceutical uses of the dipeptide tyrosine-arginine in combination with niacinamide as substance P antagonist |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3637508A (en) | 1970-03-06 | 1972-01-25 | William B Willsey | Process and composition for dissolving copper oxide |
| US4067974A (en) | 1976-01-21 | 1978-01-10 | The Purdue Frederick Company | Stabilized solid form choline salicylate compositions |
| US4954487A (en) | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| US4338311A (en) | 1980-10-27 | 1982-07-06 | Riker Laboratories, Inc. | Hydrophilic choline salicylate formulation |
| US4588590A (en) | 1981-12-21 | 1986-05-13 | Jaye-Boern Laboratories, Inc. | Method of treating keratosis and compositions useful therefor |
| IL68965A (en) | 1983-06-13 | 1987-02-27 | Rafa Labor Ltd | Topical pharmaceutical preparation comprising acetylsalicylic acid for the treatment of dermatological disorders |
| FR2581542B1 (en) | 1985-05-07 | 1988-02-19 | Oreal | TOPICAL COMPOSITIONS FOR THE TREATMENT OF SKIN BASED ON SALICYLIC ACID DERIVATIVES |
| FI930459A7 (en) * | 1992-03-27 | 1993-09-28 | Curtis Helene Ind Inc | Shampoo compositions and suspending agent therefor |
| FR2714831B1 (en) | 1994-01-10 | 1996-02-02 | Oreal | Cosmetic and / or dermatological composition containing salicylic acid derivatives and method for solubilizing these derivatives. |
| DE4420727A1 (en) | 1994-06-15 | 1995-12-21 | Rovi Gmbh | Skin-friendly aqueous liposome dispersions containing alpha-hydroxycarboxylic acids and / or alpha-hydroxyketo acids in their salt form |
| US5449519C1 (en) | 1994-08-09 | 2001-05-01 | Revlon Consumer Prod Corp | Cosmetic compositions having keratolytic and anti-acne activity |
| US5505949A (en) | 1994-10-13 | 1996-04-09 | Benitez; Juan E. | Topical treatment for acne |
| FR2743813B1 (en) | 1996-01-23 | 1998-02-20 | Oreal | STABLE GEL COMPOSITION WITH HIGH ELECTROLYTE CONTENT |
| NZ331237A (en) | 1996-02-08 | 2000-08-25 | Kligman Douglas E & Kligman Al | Superficial chemical skin peels using salicyclic acid |
| US6120756A (en) | 1998-08-19 | 2000-09-19 | Philip I. Markowitz | Topical anionic salicylate for disorders of the skin |
| US6200964B1 (en) | 1999-05-28 | 2001-03-13 | Neutrogena Corporation | Silicone gel containing salicylic acid |
| US6177413B1 (en) | 2000-03-03 | 2001-01-23 | Natalie Blahut | Stabilized aspirin compositions and method of preparation for oral and topical use |
| US8492366B2 (en) | 2002-10-07 | 2013-07-23 | Societe L'oreal S.A. | Enhancedly-solubilized beta-hydroxy acids and higher potency skin peels formulated therefrom |
| AU2002343174A1 (en) * | 2002-11-25 | 2004-06-18 | Rachid Ennamany | Betaine and salicylic acid compositions |
| CA2453013C (en) | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| US20040161392A1 (en) | 2003-02-19 | 2004-08-19 | L'oreal S.A. | Skin peeling composition and method |
| US20040248858A1 (en) | 2003-06-09 | 2004-12-09 | Parghi Kaumil H. | Cure for cancer |
| US20050002996A1 (en) | 2003-07-02 | 2005-01-06 | Milan Sojka | Sustained release compositions and controlled delivery method |
| US9089494B2 (en) | 2004-09-14 | 2015-07-28 | Coty S.A. | Ultra-violet inhibition system |
| US20060067958A1 (en) | 2004-09-24 | 2006-03-30 | Unilab Pharmatech, Ltd. | Pharmaceutical topical gel compositions |
| JP2008520652A (en) | 2004-11-22 | 2008-06-19 | ヴィーナス・レメディーズ・リミテッド | Non-aqueous liquid parenteral aceclofenac formulation |
| ATE493177T1 (en) * | 2005-03-04 | 2011-01-15 | Procter & Gamble | WASHABLE OR WIPABLE SKIN CLEANING COMPOSITIONS |
| US20070042007A1 (en) | 2005-08-19 | 2007-02-22 | Joseph Schwarz | Topical composition for delivery of salicylate esters |
| EP1948130B1 (en) | 2005-10-24 | 2013-09-11 | Precision Dermatology, Inc. | Topical pharmaceutical foam composition |
| US8685471B2 (en) | 2006-07-17 | 2014-04-01 | Tyratech, Inc. | Compositions and methods for controlling insects |
| US8337869B2 (en) | 2007-08-07 | 2012-12-25 | Gross Robert L | Analgesic cream |
| US20110091572A1 (en) | 2008-06-05 | 2011-04-21 | Davidson Richard E | Acne treatment compositions comprising nanosilver and uses |
| US8409600B2 (en) | 2009-01-23 | 2013-04-02 | J&E Solutions, Llc | Methods for prevention and/or treatment of capsular contracture |
| US20110160166A1 (en) | 2009-12-31 | 2011-06-30 | Karen Hohenstein | Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues |
-
2013
- 2013-03-08 US US13/789,780 patent/US8828979B2/en not_active Expired - Fee Related
- 2013-09-30 MX MX2015011497A patent/MX373541B/en active IP Right Grant
- 2013-09-30 WO PCT/US2013/062561 patent/WO2014137395A1/en not_active Ceased
-
2014
- 2014-08-08 US US14/454,886 patent/US20140349978A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,560 patent/US20170354734A1/en not_active Abandoned
-
2020
- 2020-03-27 US US16/832,171 patent/US12251442B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0052705A1 (en) * | 1980-11-24 | 1982-06-02 | Joel E. Bernstein, M.D. | Composition for treating acne vulgaris |
| WO1998052927A1 (en) * | 1997-05-19 | 1998-11-26 | Rosemarie Scivoletto | Composition for treating skin conditions |
| WO2000002593A2 (en) * | 1998-07-09 | 2000-01-20 | Transphyto S.A. | Cleansing and treating lotion for treating comedones |
| EP1795181A1 (en) * | 2005-12-05 | 2007-06-13 | L'Oréal | Cosmetic and pharmaceutical uses of the dipeptide tyrosine-arginine in combination with niacinamide as substance P antagonist |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200316206A1 (en) | 2020-10-08 |
| US20130261091A1 (en) | 2013-10-03 |
| US20140349978A1 (en) | 2014-11-27 |
| US20170354734A1 (en) | 2017-12-14 |
| US8828979B2 (en) | 2014-09-09 |
| MX2015011497A (en) | 2016-06-21 |
| US12251442B2 (en) | 2025-03-18 |
| MX373541B (en) | 2020-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12251442B2 (en) | Salicylic acid gel | |
| ES2327901T3 (en) | METHOD FOR PREPARING DISPERSIONS CONTAINING PHYSIOLOGICALLY ACTIVE INGREDIENTS AT HIGH PRESSURE / HIGH SHEAR. | |
| KR100690469B1 (en) | Gelled Aqueous Cosmetic Composition | |
| CN104918927B (en) | Cosmetic composition containing at least one hydrotropic agent and at least one reactive compound | |
| CN103857379B (en) | Hair care compositions and methods of use | |
| CA2625725C (en) | Surfactant-free dispersions comprising glyceryl acrylate polymers, and use thereof in topical formulations | |
| EP2964189B1 (en) | Salicylic acid gel | |
| US20140323445A1 (en) | Salicylic Acid Gel | |
| CN103860387B (en) | Salicylic acid nanostructured lipid carrier and its preparation method and application | |
| KR20100131972A (en) | Improve the appearance of your nails | |
| JP6763939B2 (en) | Viscosity-enhancing compositions for personal care products | |
| US20250262134A1 (en) | Salicylic Acid Gel | |
| Kwon et al. | Reduction of enlarged facial pore using ion‐paired amino acid through enhancement in skin permeation and exfoliation: A placebo‐controlled in vivo study | |
| WO2022259901A1 (en) | Hyaluronate skin-penetrating cosmetic | |
| JP2002322090A (en) | Antimicrobial composition | |
| JP5353168B2 (en) | Minoxidil-containing external preparation | |
| JP6221536B2 (en) | Composition for external use | |
| US8557263B1 (en) | Cosmetic composition in the form of an oil-in-water emulsion | |
| JP2810041B2 (en) | Hair restorer for scalp and hair | |
| JP2589761B2 (en) | Cosmetic additives | |
| WO2002003925A1 (en) | Method for preparing topical preparations containing skin protective agents with enhanced barrier properties | |
| CA2959542A1 (en) | Compositions and methods for mitigating skin irritation | |
| JP7590833B2 (en) | Composition for topical application to the skin | |
| CN102665664B (en) | Hairdressing product preparation method | |
| BR112019013094B1 (en) | Composition for shampoo with water reduction and process for obtaining the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13776659 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/011497 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013776659 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015021565 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112015021565 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150903 |


